SPECTRUMEDIX CORP
10KSB, EX-27.1, 2000-07-14
LABORATORY ANALYTICAL INSTRUMENTS
Previous: SPECTRUMEDIX CORP, 10KSB, EX-23.2, 2000-07-14
Next: DOBSON COMMUNICATIONS CORP, S-4, 2000-07-14



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SPECTRUMEDIX
CORPORTION AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2000 AND
1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   YEAR                    YEAR
<FISCAL-YEAR-END>                          MAR-31-2000             MAR-31-1999
<PERIOD-START>                             APR-01-1999             APR-01-1998
<PERIOD-END>                               MAR-31-2000             MAR-31-1999
<CASH>                                       2,183,458                  20,318
<SECURITIES>                                         0                       0
<RECEIVABLES>                                  181,137                  55,319
<ALLOWANCES>                                         0                       0
<INVENTORY>                                    617,191                 527,979
<CURRENT-ASSETS>                             2,996,428                 608,198
<PP&E>                                         766,108                 658,432
<DEPRECIATION>                               (290,253)               (194,896)
<TOTAL-ASSETS>                               3,992,189               1,545,372
<CURRENT-LIABILITIES>                        2,995,289               2,580,835
<BONDS>                                              0                       0
                                0                       0
                                          2                       0
<COMMON>                                         4,877                   4,059
<OTHER-SE>                                      19,910             (1,142,795)
<TOTAL-LIABILITY-AND-EQUITY>                 3,992,189               1,545,372
<SALES>                                        320,390                 317,672
<TOTAL-REVENUES>                             1,193,405                 317,672
<CGS>                                          644,384                 831,164
<TOTAL-COSTS>                                  644,384                 831,164
<OTHER-EXPENSES>                             1,632,748               2,431,571
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                              30,075                  13,527
<INCOME-PRETAX>                              (928,340)             (2,942,532)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                          (928,340)             (2,942,532)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                 (928,340)             (2,942,532)
<EPS-BASIC>                                     (0.25)                  (0.84)
<EPS-DILUTED>                                   (0.25)                  (0.84)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission